Neuropsych Drugmaker Wants Out Of Investors' IPO Data Suit

By Emilie Ruscoe · March 13, 2026, 8:52 PM EDT

Neuropsychiatric drugmaker Neumora Therapeutics Inc. seeks to shed investor claims it mischaracterized certain clinical study data ahead of its September 2023 initial public offering, arguing that the trading price decline cited in...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login